Agustin Casimiro-Garcia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2211704/publications.pdf

Version: 2024-02-01

16	623	687363 13	940533 16
papers	citations	h-index	g-index

17	17	17	801
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1. Journal of Medicinal Chemistry, 2022, 65, 757-784.	6.4	6
2	PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. Journal of Medicinal Chemistry, 2021, 64, 326-342.	6.4	29
3	Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3â€“9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase. Journal of Medicinal Chemistry, 2019, 62, 7669-7683.	6.4	14
4	Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 10665-10699.	6.4	55
5	Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. Journal of Medicinal Chemistry, 2017, 60, 1971-1993.	6.4	111
6	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chemical Biology, 2016, 11, 3442-3451.	3.4	127
7	ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling. ACS Chemical Biology, 2014, 9, 1552-1558.	3.4	51
8	Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Î³. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 767-772.	2.2	25
9	Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-Î³. Journal of Medicinal Chemistry, 2011, 54, 4219-4233.	6.4	51
10	Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action. Bioorganic and Medicinal Chemistry, 2009, 17, 2501-2511.	3.0	16
11	Synthesis and evaluation of novel Î±-heteroaryl-phenylpropanoic acid derivatives as PPARÎ±/Î³ dual agonists. Bioorganic and Medicinal Chemistry, 2009, 17, 7113-7125.	3.0	21
12	Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARÎ±/Î³ dual agonists, and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry, 2008, 16, 4883-4907.	3.0	30
13	Structure-based Drug Design of Pyrrolidine-1, 2-dicarboxamides as a Novel Series of Orally Bioavailable Factor Xa Inhibitors. Chemical Biology and Drug Design, 2007, 69, 444-450.	3.2	15
14	The Discovery of (2R,4R)â€Nâ€(4â€chlorophenyl)â€Nâ€•(2â€fluoroâ€4â€(2â€oxopyridinâ€1(2H)â€yl)phenyl)â€4â€methoxypyrrolidineâ€1,2â€dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor. Chemical Biology and Drug Design, 2007, 70, 100-112.	3.2	38
15	Progress in the discovery of Factor Xa inhibitors. Expert Opinion on Therapeutic Patents, 2006, 16, 119-145.	5.0	26
16	Investigation of the asymmetric Birch reductionâ€“alkylation of a chiral 5-arylbenzamide containing a carbamate group. Tetrahedron Letters, 2006, 47, 2739-2742.	1.4	8